Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ subsidiary - Caraco Pharmaceutical Laboratories has completed tender offer to acquire Dusa Pharmaceuticals for $8.00 per share, net to the seller thereof in cash, without interest thereon and less any applicable withholding taxes. As per the company, after the tender offer's expiration, 2,09,46,624 shares of common stock of Dusa had been validly tendered, representing nearly 82.4% of the outstanding shares of Dusa.

Caraco Pharmaceutical will move forward with a “short-form” merger under New Jersey law after exercising its top-up option under the merger agreement, and DUSA will become a wholly owned subsidiary of the company. Following the merger, DUSA's shares will cease to be traded on The NASDAQ Global Market.